Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success.

💎 ABOUT THE SPEAKER
Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca in 2023. I’ve never met Marc but I heard many great things about him.

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/

🫶 FOLLOW US

Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter):
https://x.com/FlotBio


🎙️ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free.

⭐️ SPONSORSHIP

Wanna reach 10,000+ biotech leaders at companies like BioNTech, Immunocore or Genmab? Feel free to message Nick (nick@flot.bio) to learn more.

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS
[00:00:00 ] Intro
[00:01:32 ] Behind the scene of the 2 billion-dollar exits
[00:20:48 ] Lessons on compliance analysis
[00:24:09 ] What to do when the market is against you
[00:36:08 ] Abivax: Phase II compared to standard of care
[00:42:51 ] IBD and the microbiome
[00:51:20 ] Why is 70% of the market in the US?
[00:59:07 ] The best way to sell a company is to make a great product
[01:03:48 ] Find people who inspire you
[01:10:45 ] Thanks for listening 🙏